Literature DB >> 22617356

Yohimbine depresses excitatory transmission in BNST and impairs extinction of cocaine place preference through orexin-dependent, norepinephrine-independent processes.

Kelly L Conrad1, Adeola R Davis, Yuval Silberman, Douglas J Sheffler, Angela D Shields, Sam A Saleh, Namita Sen, Heinrich J G Matthies, Jonathan A Javitch, Craig W Lindsley, Danny G Winder.   

Abstract

The alpha2 adrenergic receptor (α(2)-AR) antagonist yohimbine is a widely used tool for the study of anxiogenesis and stress-induced drug-seeking behavior. We previously demonstrated that yohimbine paradoxically depresses excitatory transmission in the bed nucleus of the stria terminalis (BNST), a region critical to the integration of stress and reward pathways, and produces an impairment of extinction of cocaine-conditioned place preference (cocaine-CPP) independent of α(2)-AR signaling. Recent studies show yohimbine-induced drug-seeking behavior is attenuated by orexin receptor 1 (OX(1)R) antagonists. Moreover, yohimbine-induced cocaine-seeking behavior is BNST-dependent. Here, we investigated yohimbine-orexin interactions. Our results demonstrate yohimbine-induced depression of excitatory transmission in the BNST is unaffected by alpha1-AR and corticotropin-releasing factor receptor-1 (CRFR(1)) antagonists, but is (1) blocked by OxR antagonists and (2) absent in brain slices from orexin knockout mice. Although the actions of yohimbine were not mimicked by the norepinephrine transporter blocker reboxetine, they were by exogenously applied orexin A. We find that, as with yohimbine, orexin A depression of excitatory transmission in BNST is OX(1)R-dependent. Finally, we find these ex vivo effects are paralleled in vivo, as yohimbine-induced impairment of cocaine-CPP extinction is blocked by a systemically administered OX(1)R antagonist. These data highlight a new mechanism for orexin on excitatory anxiety circuits and demonstrate that some of the actions of yohimbine may be directly dependent upon orexin signaling and independent of norepinephrine and CRF in the BNST.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22617356      PMCID: PMC3422490          DOI: 10.1038/npp.2012.76

Source DB:  PubMed          Journal:  Neuropsychopharmacology        ISSN: 0893-133X            Impact factor:   7.853


  71 in total

1.  The orexin system regulates alcohol-seeking in rats.

Authors:  Andrew J Lawrence; Michael S Cowen; Hong-Ju Yang; Feng Chen; Brian Oldfield
Journal:  Br J Pharmacol       Date:  2006-06-05       Impact factor: 8.739

2.  Forebrain-specific inactivation of Gq/G11 family G proteins results in age-dependent epilepsy and impaired endocannabinoid formation.

Authors:  Nina Wettschureck; Mario van der Stelt; Hiroshi Tsubokawa; Heinz Krestel; Alexandra Moers; Stefania Petrosino; Günther Schütz; Vincenzo Di Marzo; Stefan Offermanns
Journal:  Mol Cell Biol       Date:  2006-08       Impact factor: 4.272

3.  Excitatory action of hypocretin/orexin on neurons of the central medial amygdala.

Authors:  A Bisetti; V Cvetkovic; M Serafin; L Bayer; D Machard; B E Jones; M Mühlethaler
Journal:  Neuroscience       Date:  2006-09-22       Impact factor: 3.590

4.  Neuropeptide Y and corticotropin-releasing factor bi-directionally modulate inhibitory synaptic transmission in the bed nucleus of the stria terminalis.

Authors:  Thomas L Kash; Danny G Winder
Journal:  Neuropharmacology       Date:  2006-08-10       Impact factor: 5.250

5.  Stimuli linked to ethanol availability activate hypothalamic CART and orexin neurons in a reinstatement model of relapse.

Authors:  Christopher V Dayas; Tresa M McGranahan; Rémi Martin-Fardon; Friedbert Weiss
Journal:  Biol Psychiatry       Date:  2007-06-13       Impact factor: 13.382

6.  Noradrenergic inputs to the bed nucleus of the stria terminalis and paraventricular nucleus of the hypothalamus underlie hypothalamic-pituitary-adrenal axis but not hypophagic or conditioned avoidance responses to systemic yohimbine.

Authors:  Layla Banihashemi; Linda Rinaman
Journal:  J Neurosci       Date:  2006-11-01       Impact factor: 6.167

7.  The CRF1 receptor antagonist antalarmin attenuates yohimbine-induced increases in operant alcohol self-administration and reinstatement of alcohol seeking in rats.

Authors:  Peter W Marinelli; Douglas Funk; Walter Juzytsch; Stephen Harding; Kenner C Rice; Yavin Shaham; A D Lê
Journal:  Psychopharmacology (Berl)       Date:  2007-08-20       Impact factor: 4.530

8.  Extracellular-signal regulated kinase 1-dependent metabotropic glutamate receptor 5-induced long-term depression in the bed nucleus of the stria terminalis is disrupted by cocaine administration.

Authors:  Brad A Grueter; Heather B Gosnell; Christopher M Olsen; Nicole L Schramm-Sapyta; Tanya Nekrasova; Gary E Landreth; Danny G Winder
Journal:  J Neurosci       Date:  2006-03-22       Impact factor: 6.167

9.  Yohimbine impairs extinction of cocaine-conditioned place preference in an alpha2-adrenergic receptor independent process.

Authors:  Adeola R Davis; Angela D Shields; Jonathan L Brigman; Maxine Norcross; Zoe A McElligott; Andrew Holmes; Danny G Winder
Journal:  Learn Mem       Date:  2008-08-26       Impact factor: 2.460

10.  Alpha1-adrenergic receptor-induced heterosynaptic long-term depression in the bed nucleus of the stria terminalis is disrupted in mouse models of affective disorders.

Authors:  Zoé A McElligott; Danny G Winder
Journal:  Neuropsychopharmacology       Date:  2007-11-28       Impact factor: 7.853

View more
  16 in total

1.  Contrasting distribution of physiological cell types in different regions of the bed nucleus of the stria terminalis.

Authors:  Olga E Rodríguez-Sierra; Hjalmar K Turesson; Denis Pare
Journal:  J Neurophysiol       Date:  2013-08-07       Impact factor: 2.714

2.  α2A-adrenergic heteroreceptors are required for stress-induced reinstatement of cocaine conditioned place preference.

Authors:  Rafael E Perez; Aakash Basu; Bretton P Nabit; Nicholas A Harris; Oakleigh M Folkes; Sachin Patel; Ralf Gilsbach; Lutz Hein; Danny G Winder
Journal:  Neuropsychopharmacology       Date:  2020-02-19       Impact factor: 7.853

Review 3.  A Decade of Orexin/Hypocretin and Addiction: Where Are We Now?

Authors:  Morgan H James; Stephen V Mahler; David E Moorman; Gary Aston-Jones
Journal:  Curr Top Behav Neurosci       Date:  2017

Review 4.  Diminishing fear: Optogenetic approach toward understanding neural circuits of fear control.

Authors:  Natalia V Luchkina; Vadim Y Bolshakov
Journal:  Pharmacol Biochem Behav       Date:  2017-05-11       Impact factor: 3.533

5.  Contribution of Dynorphin and Orexin Neuropeptide Systems to the Motivational Effects of Alcohol.

Authors:  Rachel I Anderson; David E Moorman; Howard C Becker
Journal:  Handb Exp Pharmacol       Date:  2018

6.  Dorsal BNST α2A-Adrenergic Receptors Produce HCN-Dependent Excitatory Actions That Initiate Anxiogenic Behaviors.

Authors:  Nicholas A Harris; Austin T Isaac; Anne Günther; Kevin Merkel; James Melchior; Michelle Xu; Eghosa Eguakun; Rafael Perez; Brett P Nabit; Stephanie Flavin; Ralf Gilsbach; Brian Shonesy; Lutz Hein; Ted Abel; Arnd Baumann; Robert Matthews; Samuel W Centanni; Danny G Winder
Journal:  J Neurosci       Date:  2018-08-27       Impact factor: 6.167

7.  Noradrenergic alpha-2 receptor modulators in the ventral bed nucleus of the stria terminalis: effects on anxiety behavior in postpartum and virgin female rats.

Authors:  Carl D Smith; Christopher C Piasecki; Marcus Weera; Joshua Olszewicz; Joseph S Lonstein
Journal:  Behav Neurosci       Date:  2013-06-24       Impact factor: 1.912

Review 8.  The hypocretin/orexin system as a target for excessive motivation in alcohol use disorders.

Authors:  David E Moorman
Journal:  Psychopharmacology (Berl)       Date:  2018-03-06       Impact factor: 4.530

Review 9.  Orexin/Hypocretin and Organizing Principles for a Diversity of Wake-Promoting Neurons in the Brain.

Authors:  Cornelia Schöne; Denis Burdakov
Journal:  Curr Top Behav Neurosci       Date:  2017

Review 10.  Hypocretin (orexin) neuromodulation of stress and reward pathways.

Authors:  William J Giardino; Luis de Lecea
Journal:  Curr Opin Neurobiol       Date:  2014-07-20       Impact factor: 6.627

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.